Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Efficacy and Safety Study of Caldolor (Intravenous Ibuprofen) in Hospitalized Adult and Pediatric Burn Patients

This study has been completed.
Information provided by:
Cumberland Pharmaceuticals Identifier:
First received: January 22, 2008
Last updated: July 18, 2011
Last verified: July 2011
Results First Received: April 4, 2011  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Condition: Burns
Interventions: Drug: Caldolor
Drug: Placebo

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Participants were patients admitted to the study centers who had second and third degree thermal burns covering more than 10% total body surface area, including the face.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
Placebo (250 Milliliters Normal Saline) No text entered.
800mg Intravenous Ibuprofen No text entered.

Participant Flow:   Overall Study
    Placebo (250 Milliliters Normal Saline)     800mg Intravenous Ibuprofen  
STARTED     21     40  
COMPLETED     21     40  
NOT COMPLETED     0     0  

  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
Placebo (250 Milliliters Normal Saline) No text entered.
800mg Intravenous Ibuprofen No text entered.
Total Total of all reporting groups

Baseline Measures
    Placebo (250 Milliliters Normal Saline)     800mg Intravenous Ibuprofen     Total  
Number of Participants  
[units: participants]
  21     40     61  
[units: years]
Mean ± Standard Deviation
  30  ± 11.9     33  ± 10.8     32  ± 11.2  
Age, Customized  
[units: participants]
<=12 years old     0     0     0  
>12 years old     21     40     61  
[units: participants]
Female     11     25     36  
Male     10     15     25  
Region of Enrollment  
[units: participants]
United States     7     9     16  
India     14     31     45  

  Outcome Measures

1.  Primary:   Temperature   [ Time Frame: 0 to 24 hours ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

Results Point of Contact:  
Name/Title: Amy Rock, Doctor of Philosophy (Ph.D.)
Organization: Cumberland Pharmaceuticals
phone: 6152550068

No publications provided

Responsible Party: Amy Rock, Ph.D., Senior Manager, Regulatory Affairs, Cumberland Pharmaceuticals Inc. Identifier: NCT00606489     History of Changes
Other Study ID Numbers: CPI-CL-010
Study First Received: January 22, 2008
Results First Received: April 4, 2011
Last Updated: July 18, 2011
Health Authority: United States: Food and Drug Administration